Mudi Misgav

Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia <scp>A</scp>: safety and efficacy

Steven R. Lentz, Mudi Misgav, Margareth C. Ozelo et al. · Haemophilia · 2013 · 83 citations

Medicine, Hematology, Pharmacotherapy +15

Emicizumab treatment and monitoring in a paediatric cohort: real‐world data

Assaf Arie Barg, Tami Livnat, Ivan Budnik et al. · British Journal of Haematology · 2020 · 80 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Emicizumab prophylaxis: Prospective longitudinal real‐world follow‐up and monitoring

Assaf A. Barg, Ivan Budnik, Einat Avishai et al. · Haemophilia · 2021 · 70 citations

Medicine, Hematology, Pharmacotherapy +17

Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A

U. Martinowitz, Jens Bjerre, B. Brand et al. · Haemophilia · 2011 · 51 citations

Medicine, Pharmacokinetics, Pharmacology +15

Safety and efficacy of turoctocog alfa (NovoEight^®) during surgery in patients with haemophilia A: results from the multinational guardian^™ clinical trials

Elena Santagostino, Steven R. Lentz, Mudi Misgav et al. · Haemophilia · 2014 · 50 citations · Full text

Medicine, Hematology, Surgery +14